Key result
Alemtuzumab induction during kidney transplantation was associated with a hemodynamically significant pericardial effusion leading to cardiac tamponade, potentially due to cytokine release syndrome.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
Alemtuzumab induction may cause hemodynamically significant pericardial effusion and cardiac tamponade, potentially mediated by cytokine release syndrome.
Alemtuzumab is a humanized monoclonal antibody that has displayed great efficacy in several different areas. Not only has alemtuzumab been shown to have good success as a treatment of various types of malignancy (1, 2) but it also has been effective as an immunosuppressive induction agent and steroid and a calcineurin inhibitor–sparing agent for transplant recipients (3–7). Despite the good results and decreased rates of allograft rejection associated with the use of alemtuzumab, it does have adverse effects (7, 8). In this report, we describe a case of pericardial effusion leading to tamponade and cardiac arrest in a patient after kidney transplantation, which may be attributable to a rise in plasma cytokines. We believe that this is the first report of a pericardial effusion that could have been related to alemtuzumab administration. CASE REPORT A 55-year-old woman (155 cm tall, 67 kg in weight) with near end-stage renal disease underwent a preemptive living-donor renal transplantation. Her preoperative workup included a negative treadmill stress test with good functional capacity and no signs of myocardial ischemia, and a transthoracic echocardiogram test that showed an ejection fraction of 62% and no evidence of a pericardial effusion. Her preoperative blood urea nitrogen was 44 mg/dL, and her serum creatinine was 3.4 mg/dL. All other electrolytes were within normal limits. A complete blood count and coagulation studies were within normal limits aside from a hemoglobin level of 10.3 gm/dL and a hematocrit of 30.8%. The donor was the human leukocyte antigen–identical sister of the patient. The intraoperative course was without incident. Vascular access included a right external jugular triple lumen central venous catheter. The patient received a 30-mg alemtuzumab intravenous infusion for 4 hr. A dopamine infusion was implemented to maintain the mean arterial pressure of the patient between 80 to 100 mm Hg. There was immediate allograft function after reperfusion. The patient was extubated in the operating room and taken to the postanesthesia care unit (PACU) in stable condition. A postoperative chest radiograph performed 1 hr after the completion of the transplantation was described by radiology as showing clear lungs with a normal heart size and a normal pulmonary vasculature. There was no evidence of pneumothorax, and the tip of the external jugular catheter was in the right atrium. The patient became progressively hypotensive in the PACU, necessitating packed red blood cell transfusion and reimplementation of the dopamine infusion. However, she progressed to eventual cardiovascular collapse and was emergently taken to the operating suite for wound reexploration for suspected surgical site bleeding. A small perinephric hematoma of approximately 125 mL was evacuated without any other evidence of active bleeding. To better evaluate her cardiac function, a transesophageal echocardiography probe was inserted, and a large pericardial effusion with cardiac tamponade was diagnosed. A pericardial window was performed by means of a subxiphoid approach, and approximately 500 mL of serosanguinous, straw-colored fluid was drained immediately. There was an immediate normalization of the cardiovascular status of the patient. The patient was left intubated and transported to the intensive care unit. On postoperative day (POD) 1, the patient was able to be successfully extubated. Two separate follow-up transthoracic echocardiogram tests performed on POD 1 showed no signs of pericardial effusion. A computerized tomographic scan of the chest on POD 1 was read by the radiologist as showing minimal residual pericardial effusion, and there were no findings to indicate perforation by the central venous catheter. There continued to be a minimal serous output from the pericardial drain despite the continued use of the right external jugular catheter. She was discharged to home on POD 7 in good condition. The immunosuppression of the patient was maintained with tacrolimus monotherapy from POD 1 onward. She showed excellent graft function throughout her hospitalization. DISCUSSION We believe this to be the first case description of a hemodynamically significant pericardial effusion related to alemtuzumab induction. In a review of the available literature, there are no trials or studies specifically evaluating for pericardial fluid collections after alemtuzumab therapy. There are several reports, however, of the adverse cardiovascular effects of alemtuzumab, most notably hypotension, and reports of heart failure (8–11). As explained by Lenihan et al., and by Damaj et al., cardiac myocytes do not express the CD52 antigen and therefore are not directly targeted by alemtuzumab, but instead, the effects from systemic cytokine release contribute to the adverse cardiac effects (8, 12). Although reduced by treatment with steroids (which did occur in this case), cytokine release syndrome has been associated with alemtuzumab and is believed to be responsible for many of the adverse effects observed with first-dosage treatment (13, 14). Wing et al. showed that the cytokines interferon γ and tumor necrosis factor α were detectable 2 hr after exposure to alemtuzumab, and interleukin 6 was detectable 4 hr after exposure (15). Pericardial effusions leading to cardiac tamponade have been described with other monoclonal antibodies that caused elevated serum levels of tumor necrosis factor (adalimumab) and interleukin 6 (tocilizumab) (16, 17). The diagnosis of a pericardial effusion related to cytokine release syndrome from alemtuzumab infusion in this case is a diagnosis of exclusion and is purely speculative because no serum or pericardial fluid cytokine analysis was performed. Otherwise, highest on our differential was trauma from insertion or migration of the central line of the patient. However, the immediate postoperative chest radiograph showed no mediastinal widening or obscuring of the heart border despite infusion through the central venous catheter throughout the case and in the postoperative period. In addition, as the patient was decompensating in the PACU, packed red blood cells were in fused through the line, which we believed would have resulted in a visibly bloodier pericardial fluid. Furthermore, the catheter remained in the same position throughout POD 1 without any documented output for an 8-hr period (7A-3P) despite continued usage of the catheter (only 40 mL of pericardial drainage was documented for a 16-hr period from 11 PM on the night of surgery until 3 PM on POD 1). Imaging on POD 1 could not identify any area of perforation. In addition, this patient never required dialysis, and her preoperative blood urea nitrogen was 44 mg/dL, leading us to believe that uremic pericarditis was an unlikely cause. The patient had not been ill or febrile before operation, making an infectious cause to be unlikely. The patient had no known autoimmune or malignant disease. She had no preexisting cardiac dysfunction as demonstrated by her preoperative workup. The exact cause of the effusion is not known, but we believe that cytokine release syndrome from alemtuzumab presents a potentially plausible explanation. Cardiotoxic effects of alemtuzumab have been published, with many of the authors attributing the adverse outcomes to cytokine release associated with this medication (8, 10, 11). Therefore, any signs of hemodynamic instability within the context of alemtuzumab administration should prompt physicians to rule out life-threatening cardiopulmonary complications. Phillip S. Adams1 1 Ron Shapiro2 Ibtesam A. Hilmi1 1Department of Anesthesiology University of Pittsburgh Medical Center Pittsburgh, Pennsylvania 2Thomas E.
No takes yet. Share an insight, caveat, or question.
Adams et al. (2013) conducted a case report in End-stage renal disease undergoing kidney transplantation (n=1). Alemtuzumab was evaluated on Pericardial effusion leading to cardiac tamponade. Alemtuzumab induction during kidney transplantation was associated with a hemodynamically significant pericardial effusion leading to cardiac tamponade, potentially due to cytokine release syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: